TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2590.
Locate Jan Aushadhi KendraClinical Overview
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with a full glass of water. Swallow tablets whole; do not break, crush, or chew. Avoid taking with high-protein meals, which compete with levodopa for intestinal and blood-brain barrier amino acid transport. Complete dosing exactly as timed by your neurologist.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyskinesia, nausea, harmless reddish-brown/orange urine discoloration, diarrhea, dizziness, somnolence, orthostatic hypotension. Rare/Severe: Severe dyskinesias, hallucinations, sudden sleep onset episodes while driving, neuroleptic malignant syndrome-like reaction upon abrupt cessation, and rhabdomyolysis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Urine may turn harmless reddish-brown due to entacapone metabolites. Contraindicated with non-selective MAO inhibitors and in patients with history of melanoma or narrow-angle glaucoma. Never stop abruptly to prevent acute hyperpyrexia and rigidity.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Levodopa 100mg + Carbidopa 25mg Tablets
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Carbidopa 10mg + Levodopa 100mg Tablets
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Levodopa 200mg + Carbidopa 50mg Prolonged Release Tablets
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Entacapone Tablets 200mg
Entacapone is a reversible, selective, and peripherally acting catechol-O-methyltransferase (COMT) inhibitor. It blocks the conversion of levodopa to 3-O-methyldopa (3-OMD) in peripheral tissues, leading to sustained plasma levodopa concentrations and greater brain bioavailability. Indicated as an adjunct to levodopa and carbidopa for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").